RenovoRx annual return on equity
2021
2022
2023
2024
2025
RenovoRx Return on Equity (ROE) Growth & History (RNXT)
RenovoRx's return on equity was −225.62% for fiscal 2025.
View full RenovoRx company overviewRenovoRx annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −225.62% | +10.12 pp |
| 2024 | 2024-12-31 | −235.73% | −12.40 pp |
| 2023 | 2023-12-31 | −223.33% | −131.39 pp |
| 2022 | 2022-12-31 | −91.94% | +1733.17 pp |
| 2021 | 2021-12-31 | −1,825.11% | — |
RenovoRx quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −28.76% | −4.43 pp |
| Q1 2026 | 2026-03-31 | −42.20% | −14.76 pp |
| Q4 2025 | 2025-12-31 | −43.57% | +6.27 pp |
| Q3 2025 | 2025-09-30 | −31.11% | −0.87 pp |
| Q2 2025 | 2025-06-30 | −24.33% | +18.95 pp |
| Q1 2025 | 2025-03-31 | −27.45% | +17.70 pp |
| Q4 2024 | 2024-12-31 | −49.84% | +164.86 pp |
| Q3 2024 | 2024-09-30 | −30.24% | +207.78 pp |
| Q2 2024 | 2024-06-30 | −43.28% | +61.44 pp |
| Q1 2024 | 2024-03-31 | −45.14% | +24.01 pp |
| Q4 2023 | 2023-12-31 | −214.70% | −184.57 pp |
| Q3 2023 | 2023-09-30 | −238.02% | −214.64 pp |
| Q2 2023 | 2023-06-30 | −104.73% | −81.83 pp |
| Q1 2023 | 2023-03-31 | −69.16% | −47.62 pp |
| Q4 2022 | 2022-12-31 | −30.13% | −15.82 pp |
| Q3 2022 | 2022-09-30 | −23.39% | +80.93 pp |
| Q2 2022 | 2022-06-30 | −22.89% | — |
| Q1 2022 | 2022-03-31 | −21.54% | — |
| Q4 2021 | 2021-12-31 | −14.32% | — |
| Q3 2021 | 2021-09-30 | −104.31% | — |
RenovoRx return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, RenovoRx's return on equity increased from −1,825.11% to −225.62%, a change of +1599.49 percentage points. The latest reported quarter, Q2 2026, shows −28.76%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RenovoRx source filings ↗